Compare Ascendis Pharma A/S (ASND) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Petróleo Brasileiro SA — how do they compare? Ascendis Pharma A/S trades at $265.33 (market cap $17.74B), while Petróleo Brasileiro SA trades at $17.89 (market cap $105.14B). The key difference: Petróleo Brasileiro SA is far larger — about 5.9× Ascendis Pharma A/S's market cap, and Petróleo Brasileiro SA pays a 10.18% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | PBR | |
|---|---|---|
Market Cap | $17.74B | $105.14B |
Sector | Health | Technology |
52-Week High | $277.18 | $22.03 |
52-Week Low | $163.32 | $11.54 |
Enterprise Value | $18.11B | $167.68B |
Dividend Yield | — | 10.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Petrobras (PBR) trades at $17.32, up 1.7% with bullish technical signals and strong fundamentals. The stock shows attractive valuation metrics with P/E of 5.52 and ROE of 24.94%, supported by robust cash flow generation of $197.5B in 2025. Recent developments include strategic partnerships with Pemex and renewable energy investments, while maintaining consistent dividend payments.
PBR presents compelling value with significant upside to the $23.90 consensus target, though faces risks from commodity volatility and recent earnings miss. The company's production growth and cost discipline support long-term investment case, but investors should monitor execution on new projects and oil price sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
